All In Biotech

Drug Trial Radar · NCT04784052

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

TCRαβ+ T-cell/CD19+ B-cell Depleted Hematopoietic Grafts and a Reduced Intensity Preparative Conditioning Regimen Containing JSP191 (Briquilimab) to Achieve Engraftment and Blood Reconstitution in Patients With Fanconi Anemia

Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Dec 7, 2021

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Porteus, Matthew, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this clinical trial is to develop a cell therapy for Fanconi Anemia which enables enhanced donor hematopoietic and immune reconstitution with decreased toxicity by transplanting depleted stem cells from a donor with and without using an experimental antibody treatment called JSP-191 as a part of conditioning. This experimental treatment will hopefully cause fewer side effects than chemotherapy (the current standard of care method). Participants will be administered the conditioning regimen, are assessed until they receive the depleted stem cell infusion, and will be followed for up to 2 years after the cell infusion.

Conditions

  • Fanconi Anemia

Interventions

  • JSP191Drug

    Participants will receive a single IV dose at start of conditioning

  • CliniMACS Prodigy SystemDevice

    The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient

  • Depleted Stem Cell TransplantBiological

    TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.

  • Rabbit Anti-Thymoglobulin (rATG)Biological

    3 consecutive daily doses of rATG will be given by IV during conditioning

  • CyclophosphamideDrug

    4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning

  • FludarabineDrug

    4 consecutive daily doses of fludarabine will be given by IV during conditioning

  • RituximabDrug

    1 dose of rituximab will be given at the end of conditioning

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants without grade 3 and 4 treatment-emergent adverse events (TEAEs) (infusion related reactions).Time frame: From start of conditioning regimen administration until cell infusion (up to 30 days)
  2. Number of participants without grade 3 and 4 treatment-emergent adverse events (TEAEs) (infusion related reactions) following infusion of TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic graft transplantationTime frame: Up to 2 years post-cell infusion
  3. Number of participants able to achieve donor engraftmentTime frame: Assessed at Day +42 post-cell infusion
  4. Number of participants who are able to have donor engraftment persist at the same rate or better compared to alternative hematopoietic cell transplant regimens for this patient populationTime frame: Assessed at Day +100 post-cell infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Stanford, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.